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We review the FDA’s policies for the regulation of patient-
reported outcome (PRO) claims such as quality of life,
productivity, satisfaction and symptom reports and
suggest alternative standards for substantiation. We base
our review on FDA regulatory activities and public state-
ments in the ﬁeld of advertising substantiation. We
compare these activities to the FDA’s label substantiation
policies and policies for health-economic (HE) claim 
substantiation. There is an overt inconsistency between
the FDA’s policies for substantiation of PRO claims in
product labels and substantiation for such claims in
advertising materials. This results in a higher standard for
PRO claims in promotional vehicles than in product
labels. Rather than relying on a “substantial evidence”
standard, the FDA should consider a more ﬂexible 
standard, such as the one currently applied to informa-
tion included in the Clinical Trials section of product
labels, or adopting a “competent and reliable scientiﬁc
evidence” standard as set forth in Section 114 of the Food
and Drug Administration Modernization Act (FDAMA)
for HE data. We conclude that there needs to be greater
consistency for substantiation in product labels and pro-
motional materials. Furthermore, reconceptualizing most
PRO claims as beneﬁt extrapolations as opposed to efﬁ-
cacy information suggests a less rigorous standard is 
necessary.
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ABSTRACT
Introduction
It is now well recognized that the effects of pre-
scription drugs can be characterized by more than
traditional safety and efﬁcacy parameters. Although
clinically meaningful end points are needed to
understand a drug’s usefulness and beneﬁt as a safe
and effective therapy, the impact of a drug on a
variety of parameters—such as lifestyle, work style,
and personal and quality-of-life outcomes—has
become an important component for characterizing
the effects of a drug. Recently, Burke [1] has char-
acterized and described these types of claims as
patient-reported outcome (PRO) claims.
To make PRO claims in advertising and labeling,
pharmaceutical companies and the Food and Drug
Administration (FDA) must decide if the claims are
truthful, i.e., not false or misleading. This is the
standard speciﬁed in the Food, Drug and Cosmetic
(FD&C) Act that ensures that pharmaceutical prod-
ucts are not misbranded and that the company does
not violate the law. As a matter of regulation, the
FDA has long maintained that advertising claims
must be consistent with the approved product label
or sufﬁciently substantiated by additional data. The
nature and extent of these additional data, however,
have been a matter of debate.
In papers and presentations, experts in the ﬁeld
of outcomes assessment have suggested a variety of
methodological stipulations to assure that rigorous
standards are applied to support quality of life and
similar claims [2]. In addition, statements by FDA
ofﬁcials in regulatory letters (see below) and in pre-
sentations [3] make it clear that the FDA uses 
rigorous standards for promotional review. Unfor-
tunately, meeting such standards incurs consider-
able time and expense on behalf of companies
attempting to support such promotional efforts.
Further, as with economic claims, one may ques-
tion “how much” support is actually necessary. If a
drug has been demonstrated to be safe and effective
on primary efﬁcacy measures that are described in
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the product’s indications, what is the nature and
amount of additional evidence needed to demon-
strate support for claims that are logically con-
sistent with the clinically meaningful outcomes
noted as the product’s indications? As discussed
below, the FDA’s initial response to this question
seems to be that considerable evidence is required.
We argue that a more variable standard should
be applied to the regulation of PRO claims. This
standard should be based on the degree to which
PRO claims make representations about new uses
for a product or merely generalize established 
clinical effects into additional areas of functioning.
We believe that such a variable standard is consis-
tent with the recent congressional mandate regard-
ing ﬂexible substantiation for health-economic (HE)
claims as well as with the FDA’s own internal stan-
dards for product labels.
This paper is divided into four sections. First, we
brieﬂy review various types of advertising claims 
as a means of characterizing products; second, we
discuss the FDA’s legal and regulatory approach to
reviewing claims, and PRO claims in particular;
third, we discuss a conﬂict between the FDA’s
approach to regulating claims in product labels and
in product promotional vehicles; and fourth, we
argue that most PRO claims more aptly represent
extrapolations of the drug’s beneﬁts rather than
new uses for the drug and that these extrapolations
should require a lesser standard for substantiation.
We discuss two alternative rationales for changing
to a more ﬂexible substantiation policy. Finally, we
conclude that consistency between product labels
and promotional materials is necessary for effective
regulation and that future debate regarding the sub-
stantiation of PRO claims should include issues
such as the beneﬁts of a truthful claim and the costs
of developing substantiation.
Advertising Claims
We can characterize descriptions of any product,
including pharmaceutical products, in three differ-
ent ways [4]. First, we can describe products as
physical entities. For drugs, the physical dimensions
include not only the chemical entity, but also, the
intended uses that legally deﬁnes the chemical as a
pharmaceutical product. Other clinical outcomes
such as side effects, precautions, and warnings can
also be included in this description. This means that
the physical characteristics of a product (e.g., a
purple pill) as well as the clinical indications of the
product (e.g., treats gastroesophageal reﬂux disease
[GERD]) can be characterized as physical claims.
Second, we can describe products in terms of
their beneﬁts. For drugs, beneﬁts often correspond
to patients’ perceptions of how the drug impacts on
their life and functioning. Thus, a drug used to treat
GERD may also reduce fear and concern about
going to sleep or allow a person to participate more
freely in social activities with friends. Many of these
beneﬁts may be captured in health-related quality-
of-life (HRQL) scales that measure the impact of a
disease on a variety of dimensions [5].
PRO claims can be direct extrapolations of a
drug’s uses and effects without reference to quality-
of-life measures per se. In our GERD example,
reduction of anxiety associated with sleep and any
number of beneﬁt claims could be supported by
individual questionnaire items or scale measures,
without reference to broader quality-of-life con-
cepts. Other parameters of impact, such as prod-
uctivity or satisfaction, which measure perceived
outcomes with reference to expectations or norms,
can be considered PRO claims.
Third, we can describe products in terms of their
symbolic characteristics. Even a cursory examina-
tion of pharmaceutical advertisements reveals a
wide array of symbolism. For example, Aggrenox®
(aspirin and dipyridamole), a stroke reducing drug,
uses an egg carton to symbolize how it protects
against broken parts. Prevacid® (lansoprazole), a
proton pump inhibitor used for multiple gastroin-
testinal conditions, uses a full-service gas pump 
to symbolize its wide range of uses and therapy
options.
The FDA regulates all three types of claims in
advertising and labeling. Physical claims that merely
state the obvious (e.g., dosage form, regimen) are
often considered face valid, without the need for
further substantiation. Some extrapolation may be
permitted without substantiation (e.g., a once-a-day
dosage form may be claimed to be convenient).
However, the degree of extrapolation is limited. For
example, recently the FDA issued a guidance stating
that vague and subjective terminology describing
adverse effects (e.g., describing side effects as “well
tolerated”) will be considered misleading [6].
FDA’s Regulation of Product Labels and
Advertising Claims
Under the FD&C Act, the FDA has the respon-
sibility of assuring that product labels and promo-
tional statements are not false or misleading in any
particular. Thus, the FDA has the responsibility of
assuring that statements made on product labels or
in advertising are truthful and that the ads them-
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selves do not mislead readers or listeners. It should
be noted that there is a distinction between product
labels (i.e., package inserts) and promotional label-
ing (i.e., written, printed or graphic material that
accompanies the product, excluding the product
label). Product labels establish the conditions under
which a pharmaceutical product may be used safely
and effectively. They must be approved by the FDA
prior to initial marketing. Promotional labeling and
product advertisements are regulated by the FDA as
promotional materials and must be submitted to the
FDA at the time of their initial dissemination.
While the FDA’s responsibility to assure that
product labels, promotional labeling and advertise-
ments are truthful, how the FDA should discharge
this responsibility or what standards it should use
are open to the interpretation. For the most part,
the FDA has relied on the product label as the
arbiter of truth. The FDA expends enormous efforts
ensuring that the product label accurately repre-
sents the body of knowledge about a drug when it
is approved for marketing. In doing so, the FDA
thoroughly reviews manufacturers’ draft labeling
which it may rewrite extensively to ensure that it is
not false or misleading.
Once the product label is approved, the FDA
maintains that advertising claims that are consistent
with the product label are be truthful. Marketers do
not need to use the precise words in the label and
the FDA does not object to advertising claims as
long as the advertisement and the label convey the
same meaning. Thus, it has been long maintained
that companies wishing to make certain advertising
claims should attempt to include those claims in
their product label. However, product labels are
intended to provide necessary prescribing informa-
tion and have precise content and format speciﬁca-
tions. Thus, marketing claims may not be included
in product labels for two reasons. First, the claim
may not be sufﬁciently substantiated and therefore
not held to be truthful. Second, the claim may be
sufﬁciently substantiated but not included in the
product label because it does not provide the type
of the information speciﬁed in the content and
format regulations.
Substantiation
FDA regulations specify the nature and amount 
of evidence needed to support certain types claims
included in product labels. Speciﬁcally, claims that
describe new uses of a product or claims that
contain a drug comparison require substantial evi-
dence. Substantial evidence is further deﬁned as
consisting of one or more adequate and well con-
trolled studies on the basis of which qualiﬁed
experts could conclude that the drug has the pur-
ported effects. Usually, substantial evidence is pro-
vided by two adequate and well controlled studies.
However, recent changes in the efﬁcacy requirement
now specify that one adequate and well-controlled
study plus corroborating evidence can constitute
substantial evidence [7].
For other statements that do not describe the
drug’s uses or make comparative claims, the nature
and extent of substantiation is unclear. Such claims
must not be false or misleading and some level of
evidence is needed to support them. However, there
are no speciﬁc regulations guiding the requirements
for substantiation. Rather, the FDA has generally
relied on the approved product label, whenever pos-
sible, to determine the acceptability of promotional
claims. The nature and extent of substantiation
required depends on whether the product label is
relevant, and on the degree to which the FDA deems
the supporting evidence to be convincing.
Label Content and Format
Product labels must contain certain information in
a speciﬁed format (see 21CFR 201.57). There are
11 required sections and 2 optional sections of 
the label. Most of the speciﬁed sections describe 
a product’s risks (e.g., warnings, precautions, and
contraindications). It should be noted that the FDA
has proposed new content and format requirements
for product labels, although these address primar-
ily format issues and do not contain any different
substantiation requirements [8].
Information about a product’s beneﬁts is likely
to be conﬁned to a small number of sections.
Product uses are described in the Indications and
Uses section. As discussed above, this information
must be supported by substantial evidence. Addi-
tional parameters pertaining to the clinical effects
of a drug may be described in one of the optional
sections entitled Clinical Studies. The Clinical
Studies section of medication labels is reserved for
additional information that conveys a fuller and
more understandable presentation of the product’s
uses and effects. Information in this section must be
based upon the outcome of at least one adequate
and well-controlled study.
Thus, information presented in the Indications
and Uses section of the product label must be sup-
ported by substantial evidence (usually more than a
single study) while information presented in the
Clinical Studies section can be derived from a single
study, albeit an adequate and well-controlled study.
It should be noted that theoretically there can be
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considerable variance in the characteristics of an
adequate and well-controlled study. The FDA regu-
lations as per 21CFR 314.126 (b) [2] describe the
methodologies acceptable for adequate and well-
controlled studies which include not only placebo-
controlled trials, but also include active treatment,
no treatment, and historical controls. As a matter
of practice, nonconcurrent controlled studies are
rarely viewed as adequate and well-controlled
studies.
FDA recently disseminated a new guidance 
for the content and format for the Clinical Studies
section of the label [9]. This guidance states that the
end points discussed in the clinical trials section
should be essential to establishing effectiveness or
should provide additional useful and valid infor-
mation about the effects of the drug. The guidance
goes on to state that, “end points presented should
be end points the Agency has accepted as evidence
of effectiveness, or closely related end points that
may be more easily understood by clinicians. When
it would be informative, the Clinical Studies section
can also discuss other end points that were shown
to be affected by the drug and end points expected
to be inﬂuenced by the drug, but were not.” Thus,
the FDA seems to remain open to the inclusion of
PRO measures that are meaningful to prescribers.
The number of studies needed to support informa-
tion in the Clinical Trials section is not explicitly
discussed in the guidance. However, it does state
that the information should support effectiveness
statements and that the Clinical Studies section
should be carefully scrutinized to ensure that its
content does not imply claims for indications that
are not adequately supported. Thus, it appears that
the FDA has become more concerned about the use
of statements in the Clinical Studies section that
may be used in advertising or promotion, although
the new guidance does not bar the use of results
from a single study in this section to support adver-
tising claims.
Regulation of PRO Claims in Advertising
In recent months, the nature of the FDA regulation
of PRO claims used in advertising has become more
apparent. Examination of letters noting advertising
violations that the Division of Drug Marketing,
Advertising and Communications (DDMAC) sent
to pharmaceutical companies reveals that several
clear trends have emerged in FDA’s regulation of
quality of life and other PRO claims [10]. For
example:
In a letter dated March 7, 2000, DDMAC
objected to promotional claims for Neoral™
(cyclosporine for microemulsion). Neoral is used to
treat transplant rejection. Under the title of Unsub-
stantiated Claims, DDMAC objected to claims that
the drug affected quality-of-life issues in that it
reduced the ability to work or to manage a home,
restricted recreational activities, limited personal
and/or social relationships, and had a variety of
physical and emotional effects. DDMAC claimed
that these statements were misleading because “they
imply that Neoral has an effect on physical, mental
and social functioning that has not been demon-
strated by substantial evidence.” In the same letter,
DDMAC objected to patient satisfaction claims. In
the Neoral promotional material, under the heading
of Neoral Promotes Patient Satisfaction, the manu-
facturer provided quotes such as, “I’ve got my life
back—the Neoral difference” and “Neoral makes
me feel like a normal human being.” DDMAC
objected, stating that these were false and mislead-
ing because they made “implied and explicit claims
that Neoral promotes patient satisfaction that 
are not supported by substantial evidence. 
In a letter dated March 30, 2000, DDMAC
objected to a variety of claims for Relenza™,
(zanamivir for inhalation), used to treat the ﬂu. In
the advertisement, the manufacturer presented
several pictures and statements that emphasized the
importance of a single day. The ad contained state-
ments such as:
“Even a day can make a difference;”
“She could miss the busiest day of the year;”
“He could miss the playoff game;”
“She could miss the school bake sale;”
“He could miss the annual stockholders
meeting;”
“She could miss her granddaughter’s recital;” and
“So when the ﬂu virus gets you, you can get it
back, and get back to your life sooner.”
The FDA interpreted these statements as unsub-
stantial claims for improved functional status and
productivity.
In a letter dated March 30, 2000, DDMAC
objected to claims for a Duragesic™ (fentanyl trans-
dermal delivery system), a potent pain reliever.
Among the objections listed, DDMAC cited the
claim that the patch affected patients’ quality of life,
which required “substantial supporting evidence in
the form of adequate and well-controlled studies
designed to speciﬁcally address these outcomes.”
In a letter dated April 28, 2000, DDMAC
objected to claims for Lotronex™ (alosetron
hydrochloride), a drug used to treat certain forms
of irritable bowel syndrome (IBS). The manufac-
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turer had described the disabling effects of IBS in
terms of health-related quality of life, economic
costs, and worker productivity. DDMAC cited these
as unsubstantiated because the use of such burden
of illness claims in conjunction with promo-
tional material about the drug implied that the drug
would improve these outcomes, which was 
unsubstantiated.
In a letter dated June 20, 2001, DDMAC
objected to a web site link for Fosamax™ (alen-
dronate sodium), a drug used for osteoporosis. 
The link, entitled “Preserving your Independent
Lifestyle,” was considered misleading because it
implied an outcome that had not been demon-
strated by substantial evidence.
In a letter dated June 29, 2001, DDMAC
objected to claims that Neurontin™ (gabapentin),
an antiepileptic drug. DDMAC cited misleading
claims for quality-of-life parameters, such as social
limitations, memory difﬁculties, energy level and
work limitations. According to the letter, these
claims were based on a study that was not consid-
ered to provide substantial evidence, as it was an
uncontrolled study.
It is apparent from these DDMAC letters that
FDA has concluded that substantial evidence must
be used to support PRO claims used in advertising.
We suggest that this conclusion is in conﬂict with
the FDA’s existing policy for product labels. Further,
we believe that an alternative conceptualization for
PRO claims, with a more ﬂexible substantiation
policy, would provide a more reasonable basis for
FDA regulation than the current substantial evi-
dence standard.
Conﬂict Between Product Labels and
Promotional Policy
As suggested above, safety and efﬁcacy information
consistent with the product label is deemed truthful
and permissible for use in promotional materials.
The label consistency standard has provided a
useful framework for regulating most promotional
claims. However, claims for quality of life, produc-
tivity, and treatment satisfaction and many other
PRO outcomes are not usually described in the
product label. This raises the question regarding
how the FDA should regulate advertising claims
that are not explicitly described in the product label.
We contend that the level of substantiation
required to support a claim should be a function of
how the claim is conceptualized. Consistent with
the FDA’s policy for product labeling, if the infor-
mation suggests or implies new or alternative uses
for a drug, amounting to new indications, it should
be supported by sufﬁcient trial data as required for
inclusion in the Indications and Uses section of the
product label. If the claim provides information
about the effects of a drug that are not new indica-
tions, but useful information of relevance to practi-
tioners and patients, the FDA has historically
required “convincing evidence” as opposed to “sub-
stantial evidence” that the claims are truthful.
Following the logic used for product labels, we
propose that the amount of substantiation should
depend on where such information would belong in
the product label regardless of whether or not it 
is currently included. Certain PRO claims, such as
pain relief, often included as a subscale in quality-
of-life measurements, could indeed constitute an
indication. Pain is a diagnosed medical indication
treated with prescription medication and such
information, should be included in the Indications
and Uses section. Such claims should be supported
by substantial evidence.
However, most PRO claims contribute additional
information about the beneﬁts of the drug but do
not constitute recognized indications for which the
drug would be prescribed. The FDA reviewing divi-
sion, responsible for approving product labels, has
not regulated these claims as if they were new indi-
cations for the product. For example, Burke [3]
described 18 drug labels that included quality-of-
life statements. Examination of the labels revealed
that in all 18 cases, the quality-of-life outcomes
were included in the Clinical Trials section or a
similar section of the product label [11]. In most of
these descriptions, data from a single study was
cited. Thus, the requirement for substantial evi-
dence was not supported in these instances.
On the other hand, the FDA’s notice of promo-
tional violation letters indicates that DDMAC views
the substantiation requirements as essential for the
inclusion of PRO claims in product advertisements
and promotional materials. Recently, Burke [1] 
has stated that substantial evidence is needed if 
the assessment is not speciﬁcally mentioned in the
approved labeling. Thus, we are faced with a situ-
ation where there is a more rigorous substantiation
standard for making PRO claims in promotion than
there is for including such claims in product labels.
Furthermore, the FDA has great control over
product labels and may decide that even if such
information is sustainable scientiﬁcally, it is not nec-
essary to assure that the drug can be prescribed
safely and effectively and therefore determine that
it should not be included in the label. The FDA has
less control over what information is included in
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product advertisements. As long as the information
is truthful and sufﬁcient disclosures are provided,
manufacturers are free to advertise products on the
basis of what they believe to be important regard-
less of the FDA’s view of its relevance. Thus,
Company A could promote a product using PRO
claims that were included in the Clinical Trials
section of their product label but Company B, with
identical ﬁndings and levels of support, could not
make the same advertising claims if the FDA
thought the claims were not necessary to be
included in their product label.
We propose that the important issue for deter-
mining the sufﬁciency of substantiating data for
product advertisements should not be whether that
information is included on the label, but rather,
where on the label the information would be
included. Regardless of whether such information is
included in the label, the same standards should be
applied to the regulation of claims on both the
product label and promotional labeling.
Thus the amount and quality of data required to
support PRO claims should be based on where such
claims would be placed on the product label. Con-
sistent with the FDA’s long-held policy, the same
level of evidence should be required to support 
both promotional and label claims. If the claim is
included in the Indications and Use section, then it
should be supported by substantial evidence from
adequate and well-controlled trials. Similarly, if the
claim is included in the Clinical Trials section or
some other section, it should meet the evidentiary
standard for that section.
Implications of Alternative
Conceptualizations for Substantiation
Primary Efﬁcacy or Beneﬁt Extrapolation
Any claim related to changes in an outcome
measure after drug ingestion is likely to reﬂect on
the drug’s efﬁcacy or safety. The way in which one
conceptualizes that outcome is essential for deter-
mining the level of evidence required to substanti-
ate claims based on those data. Merely stating that
an outcome measures efﬁcacy or that it is based 
on a patient’s subjective assessment is an insufﬁ-
cient rationale for determining substantiation 
requirements.
We suggest that most PRO claims are not clini-
cal end points relevant to medical diagnoses or
effective decisions. We view most PRO claims as
describing additional beneﬁts/detriments of the
drug that are logical extrapolations of the drug’s
proven effects, although much of this information
is not relevant to product labeling. For example, 
if a drug decreases the frequency or severity of
migraine attacks, it is logical to assume that
workers who suffer from migraines would remain
more productive if they took that drug. Claims
based on a measure of increased productivity would
be consistent with the action of the drug. Physi-
cians, however, would prescribe the drug to prevent
migraine attacks rather than to increase worker
productivity. Productivity claims would not be rel-
evant to prescribing decisions, and their inclusion,
even if as part of the Clinical Studies section, would
not be warranted. Marketers might view these
claims as being of importance for managed care
organizations making coverage decisions for com-
mercial clients and for patient marketing, where
improved productivity might be considered a valu-
able beneﬁt of using the drug.
Classic marketing theory suggests that to effec-
tively present product claims to most audiences, it
is important to describe these effects in terms of the
product’s perceived beneﬁts [4]. These beneﬁts can
be expressed in terms of the psychosocial conse-
quences of using the product [12]. For example, a
drug that treats asthma may make it easier for a
patient to breath, which, in turn, may permit the
patient to be more active in social situations, which,
in turn, may improve patients’ ability to enjoy their
friendships more fully. Breathing easier, being more
socially active and enjoying friendships are all 
beneﬁts that can be attributed to a drug that treats
asthma. According to the FDA, substantial evidence
is required to support any of these claims. We
suggest that these downstream claims can be viewed
as logical extrapolations of the clinical effects of the
drug. As such, conducting the same amount of clin-
ical research as is required to support the use of the
drug as an effective treatment for asthma seems
redundant and unnecessary. While some reasonable
level of support is necessary, substantial evidence
for such claims is not warranted.
While many PRO claims are logical extensions
of a drugs known or demonstrated clinical effects,
we do not suggest that the PRO claims are merely
redundant with clinical information. There is
increasing evidence, for example, that some health-
related quality-of-life (HRQL) measures add mean-
ingful information beyond clinical measures.
Mauskopf et al. [13], found that the Nottingham
Health Proﬁle was correlated with disease progno-
sis, disease resolution and the long-term impact of
Zoster. Solomon, Skobjeranda, and Gragg [14]
found that the SF-20 subscales meaningfully distin-
guished between cluster, tension and migraine
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headaches. Wu and Lamping [15] reported that the
Activities of Daily Living Scale predicted survival
rates independent of CD4 counts and disease stage
for HIV patients. Thus, while PRO measures may
add meaningful information to a product proﬁle
and some of this information may be relevant for
prescribing decisions, we believe that the evidence
required to support promotional claims needs to be
viewed in a ﬂexible manner, based on the relevance
of the information to the prescribing decision and
on the existing research supporting the claim.
Alternative Substantiation Policy
Using the FDA’s long held label-substantiation stan-
dards and its policies of holding advertising and
product labels to the same standard, we believe it 
is inappropriate to require substantial evidence 
for most PRO promotional claims. With a broader
public policy perspective, additional questions
regarding the quantity and quality of substantiation
required to support PRO claims may be raised.
The substantiation standard for HE claims regu-
lated under Section 114 of Food and Drug Admin-
istration Modernization Act (FDAMA) provides a
useful model for a broad public policy perspective.
Under FDAMA, the FDA is directed to use a more
ﬂexible standard for the substantiation of HE infor-
mation. While the standards for clinical claims and
clinical assumptions underlying economic models
remain as standards acceptable to clinical experts,
the standards for HE information are more vari-
able. HE claims do not require substantial evidence
or even a single adequate and well-controlled study.
Rather, they require competent and reliable scien-
tiﬁc evidence for support. This standard is based on
the Federal Trade Commission’s (FTC) substantia-
tion policy, whereby companies must have a rea-
sonable basis for making marketing claims. The
FTC standard is ﬂexibly applied to promotional
material, and the requirements vary according to
the type of claim, the product, the consequences 
of a false claim, the beneﬁts of a truthful claim, 
the costs of developing substantiation, and what
experts in the ﬁeld believe is reasonable [16].
Congress passed Section 114 under the premise
that formulary members should have access to HE
information that does not meet the FDA’s tradi-
tional standards as long as the clinical basis for such
claims is based on the FDA’s traditional standard
for evidence. The conference committee report
reviewing this section of FDAMA further stated
that this provision would permit the distribution of
information that would include reasonable assump-
tions about the health-economic consequences
derived from, but not explicitly cited in, the
approved indication, as long as the information was
supported by competent and reliable scientiﬁc 
evidence [17].
This is consistent with the circumstances under
which most PRO claims would be made. Applying
this logic, clinical effects (i.e., indications and uses)
would be supported by the FDA’s substantial evi-
dence standard. However, extrapolations based on
those clinical effects would have to be supported by
competent and reliable scientiﬁc evidence. Thus, a
reasonable public policy position should hold that
substantiation for most PRO claims be based on
FTC’s competent and reliable evidence standard
rather than the FDA’s adequate and well-controlled
study standard, as long as the clinical basis for such
claims meets the substantial evidence standard.
Which Alternative?
The FDA’s substantial evidence standard establishes
an extremely high bar for PRO advertising claims.
We consider two alternative substantiation stan-
dards. Using a single adequate and well-controlled
study for most PRO claims is consistent with the
FDA’s product-labeling standards. Other than in the
cases where a PRO claim suggests a product indi-
cation not included on the approved label, a single
study using interpretable secondary end points
should provide adequate support for PRO advertis-
ing claims. It is also reasonable to use the FTC’s
competent and reliable standard to support PRO
claims under the premise that PRO claims are
logical extrapolations of a drug’s proven clinical
effects.
The issue regarding which of these latter 
standards should be applied requires further 
debate. One problem with choosing between these
two alternatives is that the difference between them
is unclear. It may be that an “adequate and well
controlled” study is methodologically congruent
with a “competent and reliable” study. The opinion
of what experts in the ﬁeld consider to be reason-
able is included among the multiple criteria listed
for enforcing the FTC’s standard. To its credit, the
FDA has met with several organizations and
solicited the views of experts in quality-of-life
research to gather perspectives on methodological
issues related to the study of PRO outcomes [3].
Thus, a body of evidence regarding standards for
conducting rigorous research in the ﬁeld of PROs is
evolving.
However, there have been no public policy
forums to discuss expert opinions of the amount of
evidence reasonably needed to support PRO claims.
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Furthermore, there have been no public debates
dealing with the impact of other aspects of compe-
tent and reliable research, such as, what are the 
consequences of a false claim, what are the beneﬁts 
of a truthful claim, and what are the costs of de-
veloping substantiation? Thus, before a deciding
which standard to use, we must deﬁne more pre-
cisely what the level of evidence required adequately
respond to those standards must be deﬁned more
precisely, and a more complete discussion of the
public policy impact of applying varying standards
is essential.
Impact of Alternative Substantiation
Standards
One important issue that needs to be debated is how
a lesser standard for PRO claims would impact the
widespread distribution of “bad information” and
its public health effect [18]. One would expect that
if the FDA lowered its standards, companies would
develop only the lower level of substantiation. How
this would impact on the dissemination of false and
misleading claims and, ultimately, how this could
inﬂuence drug usage decisions and prescribing prac-
tices are issues that remain to be addressed.
Calfee and Papplardo [19] have suggested that
advertising claims should be regulated by consider-
ing the impact of dissemination of false claims and
of not disseminating truthful claims. Using a tradi-
tional truth table, the impact of changing standards
for dissemination of advertising can be viewed as
follows (Table 1):
If a lower standard were applied, one would
expect an increased number of Type I errors (false
claims distributed). However, there would also 
be fewer Type II errors (truthful claims not 
distributed).
To consider the impact of switching Type I for
Type II error in promotion, the role of PRO claims
in product decision making must be considered. It
is difﬁcult to assess precisely the impact that PRO
claims have on prescribing or usage decisions. Jack
[20] has demonstrated how sales of a pharmaceuti-
cal product can increase following the publication
of positive study of quality-of-life outcomes.
Indeed, PRO outcomes may provide information
about differential product beneﬁts. However, unlike
clinical information that describes a drug’s indica-
tions and usage, most PRO claims would not
provide information about the type of therapeutic
intervention needed in a particular prescribing situ-
ation. Thus, PRO claims could inﬂuence which drug
within a therapeutic class is prescribed (secondary
demand) but they are less likely to inﬂuence which
therapeutic class of drugs should be used (primary
demand). As such, a greater number of PRO claims
in marketplace would be more likely to impact on
brand or within class competition rather than on
selection of the most appropriate class of medica-
tion for treatment of an individual. Under these cir-
cumstances, greater tolerance for Type I errors may
be worth the risk, given the greater information
made available to help in brand selection decisions.
Conclusion: Developing a Reasonable Policy 
This paper proposes three options for substantia-
tion of PRO claims used in advertising: substantial
evidence, label consistency, and competent and reli-
able scientiﬁc evidence. The FDA appears willing to
accept substantial evidence for advertising claims
and label consistency for products that include such
claims as part of their approved package inserts
regardless of whether the information was origi-
nally supported by substantial evidence. Products
for which labeled claims do not exist, require sub-
stantial evidence to support the use of PRO claims
in advertising materials.
We argue that PRO claims often represent logical
extrapolations of clinical effects. Even if PRO
claims add new information that would not be
anticipated, the claim is based on the approved 
clinical indication for the medication. Given this
premise, it is unreasonable to expect that PRO
claims should require the same level of substantia-
tion as would a new indication for the medication.
Rather, a more reasonable approach is to allow for
the dissemination of PRO claims that are based on
a reasonable amount of substantiation.
Further, the evidentiary standards for product
labels and advertising should be consistent. Labels
require different levels of evidence for the Indica-
tions and Use section and for the Clinical Trials
section. We suggest that the same standards be
applied to advertising. Although consistency may
not always the best policy, inconsistencies raise
questions. Having a logical rationale for public poli-
cies that result in a heavy regulatory burden goes 
a long way to justifying regulatory principles.
Table 1 Truth table
Truthful claim False claim
Distributed claim Correct decision Type I error
Claim not Type II error Correct decision
distributed
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Without a logical rationale for differences between
the FDA’s product label and advertising policies,
regulatory requirements appear arbitrary and 
capricious.
We do not differentiate strongly between a 
labeling consistency and competent and reliable
standard. This is because both are more ﬂexible
than substantial evidence in their application. and
indeed, may represent the same level of evidence
under certain circumstances. We suggest that a
single study may sufﬁce to support many PRO
claims. The methodological standards for such a
study deserve great attention. While there has been
considerable discussion regarding the methodologi-
cal rigor for such studies [21], there has been insuf-
ﬁcient discussion of costs of such studies, the price
paid for setting a high bar for dissemination of these
claims, and the consequences of disseminating
information that may not be truthful. These factors
should be considered in future discussions.
The language of advertising is often optimistic
with claims that emphasize the beneﬁts of the
product to the patient, rather than merely describ-
ing the clinical effects. PRO claims help convey this
information and play an important role in com-
municating the real value of pharmaceuticals to
patients, managed care organizations and
providers. On the other hand, the FDA has con-
cluded that PRO claims represent end points indica-
tive of a drug’s clinical efﬁcacy regardless of the
nature of the individual claims. The FDA’s recent
objection to an implied claim that a drug could help
preserve an independent lifestyle on the basis that
such an outcome has not been demonstrated by sub-
stantial evidence clearly shows a lack of discrimi-
nation between meaningful clinical end points
relevant for prescribing decisions and extrapola-
tions of a drug’s effects of relevance to consumer
marketing. It is a matter of debate and conjecture
why PRO claims should be required to have the
same level of evidence as new indications. Other
descriptions of a drug’s beneﬁt, using somewhat less
speciﬁc or more symbolic language or graphics, are
not regulated as heavily.
In conclusion, DDMAC has been remarkably
open to developing policies for the regulation of
PRO claims and outcome researchers have con-
tributed considerable time and effort in elevating
this debate by discussing methodological options
for studies involving PRO end points. This paper is
intended to add to this developing debate by focus-
ing on another area of consideration—how such
claims should be regulated. We look forward to
these discussions.
Support for this paper was provided by GlaxoSmithKline.
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